In response to a request from the House Ways and Means Committee’s Health Subcommittee for suggestions from stakeholders on ways to improve the delivery of Medicare services and eliminate statutory and regulatory obstacles to more effective care delivery, NAUH has urged the committee to compel CMS to withdraw its proposed changes in reimbursement for prescription drugs purchased by hospitals under the federal government’s 340B prescription drug discount program.

The Centers for Medicare & Medicaid Services’ proposed outpatient prospective payment system rule for 2018, published in July, calls for significant reductions in federal reimbursement for drugs purchased by hospitals for low-income patients under the federal 340B prescription drug discount program.  If implemented, such a change could cause considerable financial harm to private safety-net hospitals and potentially jeopardize access to care for the low-income patients these hospitals serve.

See NAUH’s message to the House Ways and Means Committee here.